ArticleInternational journal of cancer2014
Origin and pharmacological modulation of tumor-associated regulatory dendritic cells.
Article in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Stimulation of regulatory dendritic cells suppresses cytotoxic T cell function and alleviates DEN-induced liver injury, fibrosis and hepatocellular carcinoma.Frontiers in immunology · 2025Article
- The immune microenvironment of lung adenocarcinoma featured with ground-glass nodules.Thoracic cancer · 2024Review
- Dendritic Cells in Shaping Anti-Tumor T Cell Response.Cancers · 2024Review
- Elucidating granulocytic myeloid-derived suppressor cell heterogeneity during Staphylococcus aureus biofilm infection.Journal of leukocyte biology · 2024Article
- Review
- The role of tumor microenvironment on cancer stem cell fate in solid tumors.Cell communication and signaling : CCS · 2023Review
- Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance.Antioxidants (Basel, Switzerland) · 2023Review
- Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.Frontiers in immunology · 2023Review
- Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer.Journal of the National Cancer Center · 2022Review
- Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.Cancer immunology, immunotherapy : CII · 2022Article
- Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy.Oncogenesis · 2022Review
- The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.Experientia supplementum (2012) · 2022Article
- Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands.BioImpacts : BI · 2022Review
- A Fibrinogen Alpha Fragment Mitigates Chemotherapy-InducedFrontiers in oncology · 2021Article
- Targeting Tumor Microenvironment by Small-Molecule Inhibitors.Translational oncology · 2020Review
- Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives.Cancer communications (London, England) · 2019Review
- Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups.Nanoscale · 2018Article
- Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.PloS one · 2018Article
- The role of toll-like receptor 4 in tumor microenvironment.Oncotarget · 2017Review
- Myeloid-derived suppressor cells and tumor escape from immune surveillance.Seminars in immunopathology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Protumorigenic activity of immune regulatory cells has been proven to play a major role in precluding immunosurveillance and limiting the efficacy of anticancer therapies. Although several approaches have been offered to deplete myeloid-derived suppressor cells (MDSC) and regulatory T cells, there are no data on how to control suppressive dendritic cell (DC) accumulation or function in the tumor environment. Although immunosuppressive function of DC in cancer was implicated to immature and plasmacytoid DC, details of how conventional DC (cDC) develop immunosuppressive properties remain less understood. Here, we show that the development of lung cancer in mice was associated with fast accumulation of regulatory DC (regDC) prior to the appearance of MDSC. Using the in vitro and in vivo approaches, we demonstrated that (i)both cDC and MDSC could be polarized into protumor regDC in the lung cancer environment; (ii) cDC → regDC polarization was mediated by the small Rho GTPase signaling, which could be controlled by noncytotoxic doses of paclitaxel; and (iii) prevention of regDC appearance increased the antitumor potential of DC vaccine in lung cancer. These findings not only bring new players to the family of myeloid regulatory cells and provide new targets for cancer therapy, but offer novel insights into the immunomodulatory capacity of chemotherapeutic agents used in low, noncytotoxic doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.